Companies Alaunos Therapeutics, Inc.
Alaunos Therapeutics CEO salary & total pay, FY2025: $668K
Alaunos Therapeutics (TCRT) CEO salary, fiscal 2025: Holger Weis was paid a salary of $103,566 and $667,766 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Alaunos Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Holger Weis's complete compensation dossier
A PDF and a CSV sent to your email: Holger Weis's pay in every fiscal year Alaunos Therapeutics, Inc. reported it, line by line, with Holger Weis's equity grants and Alaunos Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,986,946FY2023
- $392,500FY2024
- $667,766FY2025
CEO total pay was $667,766 in fiscal 2025 (Holger Weis), up from $392,500 in fiscal 2024 (Kevin Boyle, the CEO that year).
FY2025: salary $103,566 · bonus $0 · stock awards $0 · option awards $564,200
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Holger Weis | $103,566 | $0 | $0 | $564,200 | $0 | $0 | $0 | $667,766 |
| Chief Executive Officer since July 2025 | ||||||||
| Melinda Lackey | 0 | 0 | 0 | 3,087 | 0 | 0 | 249,335 | 250,604 |
| Former Legal & Administration, Corporate Secretary | ||||||||
| Ferdinand Groenewald | 0 | 0 | 25,000 | 11,988 | 0 | 0 | 180,000 | 216,988 |
| Vice President, Finance | ||||||||
| Dale Hogue | 139,744 | 0 | 0 | 3,748 | 0 | 0 | 0 | 143,492 |
| Former Interim Chief Executive Officer as of July 2025 | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Holger Weis | $667,766 | — | — | — |
| Melinda Lackey | 250,604 | 430,370 | 831,737 | ↓ −179,766 |
| Ferdinand Groenewald | 216,988 | 162,304 | — | ↑ +54,684 |
| Dale Hogue | 143,492 | 308,344 | 48,153 | ↓ −164,852 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company believes long-term equity incentive compensation is a critical component of its executive compensation program that links the interests of executive officers with those of stockholders. Stock options are used to align executives' realizable compensation with the creation of stockholder value and serve as an effective long-term incentive vehicle to retain talent and incentivize performance.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer and Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Holger Weis | OPTION | 2025-07-02 | — | — | 130,000 | — | — |
Vehicle mix — grant-date fair value by award type
Grant-level vehicle detail not disclosed.
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Ferdinand Groenewald | Option | 469 | 1,406 | 2.42 | — |
| Ferdinand Groenewald | Option | 2,250 | 750 | 1.46 | — |
| Holger Weis | Option | 40,625 | 89,375 | 5.02 | — |
| Holger Weis | Option | 1,000 | — | 646.5 | — |
| Holger Weis | Option | 208 | — | 646.5 | — |
| Holger Weis | Option | 666 | — | 123 | — |
| Holger Weis | Option | 666 | — | 72 | — |
| Holger Weis | Option | 452 | — | 10.3 | — |
| Holger Weis | Option | 1,920 | — | 10.3 | — |
| Holger Weis | Option | 10,904 | — | 2.92 | — |
| Holger Weis | Option | 13,676 | — | 2.32 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jaime VieserIndependent · Audit · Compensation · Corporate Governance and Nominating | $0 | $84,875 | $0 | — | — | $84,875 |
| Robert W. PostmaIndependent · Audit · Compensation · Corporate Governance and Nominating | 0 | 79,050 | 0 | — | — | 79,050 |
| Michael A. JermanIndependent · Audit · Compensation · Partial-year service · Newly elected | 0 | 13,221 | 38,744 | — | — | 51,965 |
| Holger WeisEmployee director | 0 | 0 | 48,478 | — | — | 48,478 |
| Robert J. Hofmeister, Ph.DIndependent · Partial-year service | 17,750 | 0 | 0 | — | — | 17,750 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $17,750 |
| Equity awards (grant-date value) | $177,146 |
| All other compensation | $0 |
| Total cost of the board | $194,896 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Alaunos Therapeutics as a peer
Companies that benchmark against TCRT
No companies currently name TCRT as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Alaunos Therapeutics, Inc. | 2025 | Holger Weis | $103,566 | $0 | $564,200 | $0 | $667,766 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-07-03 | 232,638 | 144,957 | 3,566 | 61.03% | Passed |
| 2024 | 2024-06-06 | 1,851,846 | 1,032,789 | 85,111 | 62.36% | Passed |
| 2023 | 2023-06-06 | 85,893,572 | 20,980,848 | 1,948,700 | 78.93% | Passed |
| 2022 | 2022-06-13 | 88,627,065 | 7,777,874 | 5,651,319 | 86.84% | Passed |
| 2021 | 2021-05-19 | 98,887,173 | 6,555,935 | 464,677 | 93.37% | Passed |
| 2020 | 2020-06-29 | 76,263,368 | 58,155,226 | 1,097,414 | 56.28% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-07-03 | 61.03%a |
| 2024 | 2024-06-06 | 62.36%b |
| 2023 | 2023-06-06 | 78.93%c |
a. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers -- The affirmative vote of a majority in voting power of shares of stock present in person or represented by proxy and entitled to vote thereon. | Abstentions: Against”.
b. Approved under the standard stated in the filing — “Approval, on an advisory basis, of the compensation of our named executive officers -- "For" votes from the holders of a majority of shares present in person or represented by proxy and entitled to vote on the matter. | Abstentions: Against”.
c. Approved under the standard stated in the filing — “Abstentions will have the same effect as Against votes on Proposal 2, Proposal 3, the Reverse Stock Split Proposal, the Authorized Stock Increase Proposal and the Adjournment Proposal, and will have no effect on Proposals 1 and 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Holger Weis | Chief Executive Officer | 2026-05-22 | A | 3,700 | $2 | $8,769 | Common | Form 4 ↗ |
| Holger Weis | Chief Executive Officer | 2026-06-12 | A | 7,761 | 2 | 17,540 | Common | Form 4 ↗ |
| Holger Weis | Chief Executive Officer | 2026-06-30 | A | 3,880 | 2 | 8,769 | Common | Form 4 ↗ |
| Jaime Vieser | Director | 2026-07-23 | A | 8,789 | 2 | 16,875 | Common | Form 4 ↗ |
| Robert W. Postma | Director | 2026-07-23 | A | 8,463 | 2 | 16,249 | Common | Form 4 ↗ |
| Michael A. Jerman | Director | 2026-07-23 | A | 8,138 | 2 | 15,625 | Common | Form 4 ↗ |
| Holger Weis | CEO | 2026-07-23 | A | 4,568 | 2 | 8,771 | Common | Form 4 ↗ |
| Holger Weis | CEO | 2026-08-06 | A | 4,363 | 2 | 8,770 | Common | Form 4 ↗ |
| Holger Weis | CEO | 2026-10-06 | A | 23,564 | 1 | 17,541 | Common | Form 4 ↗ |
| Robert W. Postma | Director | 2026-10-06 | A | 21,829 | 1 | 16,250 | Common | Form 4 ↗ |
| Jaime Vieser | Director | 2026-10-06 | A | 22,669 | 1 | 16,875 | Common | Form 4 ↗ |
| Michael A. Jerman | Director | 2026-10-06 | A | 20,990 | 1 | 15,625 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (28 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Holger Weis. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 667,766. View filing ↗
- Section 01, Melinda Lackey. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 250,604. View filing ↗
- Section 01, Ferdinand Groenewald. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 216,988. View filing ↗
- Section 01, Dale Hogue. 10-K/A, filed 2026-04-30. Section “Executive Compensation” · page 10. As printed: 143,492. View filing ↗
- Section 03, Holger Weis OPTION. DEF 14A, filed 2026-04-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Jaime Vieser. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 84,875. View filing ↗
- Section 08, Robert W. Postma. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 79,050. View filing ↗
- Section 08, Michael A. Jerman. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 51,965. View filing ↗
- Section 08, Holger Weis. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 48,478. View filing ↗
- Section 08, Robert J. Hofmeister, Ph.D. DEF 14A, filed 2026-04-30. Section “Director Compensation”. As printed: 17,750. View filing ↗
- Section 02, Holger Weis 2026-05-22. Form 4, filed 2026-05-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holger Weis 2026-06-12. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holger Weis 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jaime Vieser 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert W. Postma 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. Jerman 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holger Weis 2026-07-23. Form 4, filed 2026-07-27. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holger Weis 2026-08-06. Form 4, filed 2026-08-11. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Holger Weis 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert W. Postma 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jaime Vieser 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael A. Jerman 2026-10-06. Form 4, filed 2026-10-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-07-10. Item 5.07 · say-on-pay result. As reported: 61.03% (votes for as printed: 232,638). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-12. Item 5.07 · say-on-pay result. As reported: 62.36% (votes for as printed: 1,851,846). View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-12. Item 5.07 · say-on-pay result. As reported: 78.93% (votes for as printed: 85,893,572). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 17,750 + equity 177,146 + all other 0 = 194,896, summed across the director compensation table rows.
- Alaunos Therapeutics, Inc. (subject), Section 10b CEO total. 10-K/A, filed 2026-04-30. CEO total compensation as printed in Alaunos Therapeutics, Inc.'s own proxy. As printed: 667,766. View filing ↗